In August of 2009, the FDA notified healthcare professionals that it has completed its analysis of TNF-alpha blocking agents and concluded that there is an increased risk of lymphoma and other cancers associated with the use of these drugs in children and adolescence [68]. This evidence concerns the gene TNF and cancer.